This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-19 and is reviewed periodically as new material appears.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Common matrix | Plasma or serum | Collected under controlled conditions |
| Primary method | Liquid chromatography–tandem mass spectrometry | Structural specificity |
| Alternative method | Immunoassay | Lower specificity, higher throughput |
| Reporting unit | ng/mL | Concentration in matrix |
| Key validation item | Selectivity | Interference from related peptides |
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
=== Solid phase extraction === Solid phase extraction which separates long polymers like DNA from other substances found in the cells. This is similar to magnetic beads, where the solid phase is fixed and selectively binds a cellular component, allowing for its isolation.
== Clinical significance == Gastroesophageal reflux disease (GERD) is a common disorder that occurs when stomach acid repeatedly flows back into the esophagus, this backwash of acid (reflux) also known as heartburn can irritate the lining of the esophagus. Most people are able to manage the discomfort of GERD with lifestyle changes and medications, notably proton pump inhibitors, and H2 blockers. Antacids may also be used to neutralise gastric acid. Sometimes, surgery may be needed to ease symptoms. Chronic inflammation of the gastric mucosa can lead to atrophic gastritis resulting in a decreased secretion of gastric acid, and consequent digestive problems. In hypochlorhydria and achlorhydria, gastric acid is either low or absent, respectively. This can potentially lead to less protection against ingested pathogens such as Vibrio or Helicobacter bacteria. In Zollinger–Ellison syndrome gastrin levels are increased, leading to excess gastric acid production, which can cause gastric ulcers. Hypercalcemia also increases gastrin and gastric acid and can cause ulcers. In diseases featuring excess vomiting, hypochloremic metabolic alkalosis (decreased blood acidity by H+ and chlorine depletion) may develop.
=== Boer organization and skills === War was declared on 11 October with a Boer offensive into the British-held Natal and Cape Colony areas. The Boers had about 33,000 soldiers, and outnumbered the British, who could move only 13,000 troops to the front line. The Boers had no problems with mobilisation, since the independent Boers had no regular army units, apart from the Staatsartillerie (Dutch for 'State Artillery'). As with the First Boer War, since most of the Boers were members of civilian militias, none had adopted uniforms or insignia. Only the members of the Staatsartillerie wore light green uniforms.
Sources: en.wikipedia.org
==== Victoria College fine arts ==== On 1 January 1992 further expansion of the college took place when the fine arts programs of the former Faculty of Art and Design, Victoria College (formerly Prahran College of Advanced Education), were incorporated into the School of Art.
Soft corals have no solid exoskeleton as such. However, their tissues are often reinforced by small supportive elements known as sclerites made of calcium carbonate. The polyps of soft corals have eight-fold symmetry, which is reflected in the Octo in Octocorallia. Soft corals vary considerably in form, and most are colonial. A few soft corals are stolonate, but the polyps of most are connected by sheets of tissue called coenosarc, and in some species these sheets are thick and the polyps deeply embedded in them. Some soft corals encrust other sea objects or form lobes. Others are tree-like or whip-like and have a central axial skeleton embedded at their base in the matrix of the supporting branch. These branches are composed of a fibrous protein called gorgonin or of a calcified material.
=== Mechanism of action === Gepotidacin's primary mechanism of action involves inhibiting bacterial DNA replication, specifically targeting DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes are vital for bacterial processes such as replication, transcription, and cell division, as they regulate the topological state of DNA during these activities. Gepotidacin binds to the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV. Research has shown that this interaction occurs within a pocket formed by these subunits, located between the scissile DNA bonds. By binding in this region, gepotidacin inhibits the activity of these enzymes, thereby impairing bacterial replication. This mechanism of action is distinct from other antibiotic classes, including fluoroquinolones.
Physical exercise is often recommended as a means of improving motor skills, fitness, muscle and bone strength, and joint function. Exercise has several effects upon muscles, connective tissue, bone, and the nerves that stimulate the muscles. One such effect is muscle hypertrophy, an increase in size of muscle due to an increase in the number of muscle fibers or cross-sectional area of myofibrils. Muscle changes depend on the type of exercise used. Generally, there are two types of exercise regimes, aerobic and anaerobic. Aerobic exercise (e.g. marathons) involves activities of low intensity but long duration, during which the muscles used are below their maximal contraction strength. Aerobic activities rely on aerobic respiration (i.e. citric acid cycle and electron transport chain) for metabolic energy by consuming fat, protein, carbohydrates, and oxygen. Muscles involved in aerobic exercises contain a higher percentage of Type I (or slow-twitch) muscle fibers, which primarily contain mitochondrial and oxidation enzymes associated with aerobic respiration. On the contrary, anaerobic exercise is associated with activities of high intensity but short duration, such as sprinting or weight lifting. The anaerobic activities predominately use Type II, fast-twitch, muscle fibers. Type II muscle fibers rely on Gluconeogenesis for energy during anaerobic exercise. During anaerobic exercise, type II fibers consume little oxygen, protein and fat, produce large amounts of lactic acid and are fatigable.
Sources: en.wikipedia.org
In the 1918 general election, Lloyd George, hailed as "the Man Who Won the War", led his coalition into a khaki election. Lloyd George and the Conservative leader Bonar Law wrote a joint letter of support to candidates to indicate they were considered the official Coalition candidates—this "coupon", as it became known, was issued against many sitting Liberal MPs, often to devastating effect, though not against Asquith himself. The coalition won a massive victory: Labour increased their position slightly, but the Asquithian Liberals were decimated. Those remaining Liberal MPs who were opposed to the Coalition Government went into opposition under the parliamentary leadership of Sir Donald MacLean who also became Leader of the Opposition. Asquith, who had appointed MacLean, remained as overall Leader of the Liberal Party even though he lost his seat in 1918. Asquith returned to Parliament in 1920 and resumed leadership. Between 1919 and 1923, the anti-Lloyd George Liberals were called Asquithian Liberals, Wee Free Liberals or Independent Liberals. Lloyd George was increasingly under the influence of the rejuvenated Conservative party who numerically dominated the coalition. In 1922, the Conservative backbenchers rebelled against the continuation of the coalition, citing, in particular, Lloyd George's plan for war with Turkey in the Chanak Crisis, and his corrupt sale of honours. He resigned as prime minister and was succeeded by Bonar Law.
Selenocysteine (symbol Sec or U, in older publications also as Se-Cys) is the 21st proteinogenic amino acid. Selenoproteins contain selenocysteine residues. Selenocysteine is an analogue of the more common cysteine with selenium in place of the sulfur. Selenocysteine is present in several enzymes (for example glutathione peroxidases, tetraiodothyronine 5′ deiodinases, thioredoxin reductases, formate dehydrogenases, glycine reductases, selenophosphate synthetase 2, methionine-R-sulfoxide reductase B1 (SEPX1), and some hydrogenases). It occurs in all three domains of life, including important enzymes (listed above) present in humans. Selenocysteine was discovered in 1974 by biochemist Thressa Stadtman at the National Institutes of Health.
== External links == The MEROPS online database for peptidases and their inhibitors: A02.001 Archived 2005-01-23 at the Wayback Machine Proteopedia HIV-1_protease - the HIV-1 protease structure in interactive 3D. Proteopedia Flaps_Morph_for_HIV_Protease - Animation of the flaps opening and closing based on X-ray crystal structures. HIV-1+Protease at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
== Diagnosis == Acrocyanosis is diagnosed clinically, based on a medical history and physical examination; laboratory studies or imaging studies are not necessary. The normal peripheral pulses rule out peripheral arterial occlusive disease, where arterial narrowing limits blood flow to the extremities. Pulse oximetry will show a normal oxygen saturation. Unlike the closely related Raynaud's phenomenon, cyanosis is continually persistent. In addition, there is usually no associated trophic skin changes, localized pain, or ulcerations. Capillaroscopy and other laboratory methods may be helpful but only complement clinical diagnosis in unclear cases, especially when connective tissue disorders may be present.
Nine months earlier, he figured out that Starman's staff had imparted cosmic energy into him that was slowly healing his body. He therefore formed an alliance with the JSA's old enemy Ultra-Humanite and the surviving Dragon King to dig up his body and revive him. His plan was to transplant the Ultra-Humanite's brain into Starman's body to be his puppet that he would use to manipulate Stargirl and her JSA and become president as a mouthpiece for Icicle to enact his policies, since Starman was a beloved hero everyone admired, and the Dragon King's brain into the Ultra-Humanite's albino gorilla body for the former to "defeat" as Starman alongside Jordan's son. Christopher James Baker as Henry King Sr. / Brainwave (season 1; guest season 2):A member of the ISA with psionic abilities, the father of Henry King Jr. and a successful neurosurgeon at Blue Valley Medical Center. Baker stated that Henry King Sr. was the "mask" of Brainwave, as opposed to the other way around, believing Brainwave "is the true being". Amy Smart as Barbara Whitmore: Courtney's mother and Pat Dugan's wife who strives to balance her work and home life. After her marriage to Pat, she initially serves as a surrogate mother to her stepson Mike and also to Courtney's JSA teammates after discovering Pat and Courtney's secrets. Luke Wilson as Pat Dugan / S.T.R.I.P.E.:Courtney's stepfather, the former sidekick to Starman, and a mechanic who owns a repair garage where he stores a 15-foot robotic vehicle of his own creation made from spare car parts.
Sources: en.wikipedia.org
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.
Mass spectrometry identifies molecules by mass-to-charge transitions, which reduces interference from related peptides. Immunoassays run faster but can cross-react. Structural confirmation usually requires the mass spectrometric approach.
Cardiovascular outcomes, long-term safety, and weight regain after stopping treatment are unresolved. These questions need years of follow-up data. Published evidence covers only limited treatment durations.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.